Key result
Vascular complications during IABP-supported PCI increased in-hospital morbidity but were not associated with adjusted 12-month mortality.
Why the study?
The impact of a vascular complication in the setting of intraaortic balloon pump supported PCI on clinical outcomes was unclear.
Does the occurrence of a vascular complication worsen clinical outcomes in patients undergoing IABP-supported PCI?
Cohort (n=9,970)
Yes
Does the occurrence of a vascular complication worsen clinical outcomes in patients undergoing IABP-supported PCI?
Vascular complications during IABP-supported PCI increase in-hospital morbidity (transfusion, AKI, MI) but do not significantly impact in-hospital or 1-year mortality.
Answers are grounded in this paper and cite their sources.
Requires careful monitoring to mitigate in-hospital morbidity in IABP-supported PCI; leaves open whether complications independently influence mortality.
INTRODUCTION: The impact of a vascular complication (VC) in the setting of intraaortic balloon pump (IABP) supported PCI on clinical outcomes is unclear. METHODS: Using data from the BCIS National PCI Database, multivariate logistic regression was used to identify independent predictors of a VC. Propensity scoring was used to quantify the association between a VC and outcomes. RESULTS: Between 2007 and 2014, 9,970 PCIs in England and Wales were supported by IABP (1.6% of total PCI), with 224 femoral VCs (2.3%). Annualized rates of a VC reduced as the use of radial access for PCI increased. The independent predictors of a VC included a procedural complication (odds ratio [OR] 2.9, p < .001), female sex (OR 2.3, p < .001), PCI for stable angina (OR 3.47, p = .028), and use of a glycoprotein inhibitor (OR 1.46 [1.1:2.5], p = .04), with a lower likelihood of a VC when radial access was used for PCI (OR 0.48, p = .008). A VC was associated with a higher likelihood of transfusion (OR 5.7 [3.5:9.2], p < .0001), acute kidney injury (OR 2.6 [1.2:6.1], p = .027), and periprocedural MI (OR 3.2 [1.5:6.7], p = .002) but not with adjusted mortality at discharge (OR 1.2 [0.8:1.7], p = .394) or 12-months (OR 1.1 [0.76:1.56], p = .639). In sensitivity analyses, there was a trend towards higher mortality in patients experiencing a VC who underwent PCI for stable angina (OR 4.1 [1.0:16.4], p value for interaction .069). Discussion and Conclusions Although in-hospital morbidity was observed to be adversely affected by occurrence of a VC during IABP-supported PCI, in-hospital and 1-year survival were similar between groups.
No takes yet. Share an insight, caveat, or question.
Kinnaird et al. (2021) conducted a cohort in Patients undergoing intraaortic balloon pump (IABP) supported percutaneous coronary intervention (PCI) (n=9,970). Vascular complication vs. No vascular complication was evaluated on 12-month mortality (OR 1.1, 95% CI 0.76-1.56, p=0.639). Vascular complications during IABP-supported PCI increased in-hospital morbidity but were not associated with adjusted 12-month mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: